RxSight (RXST) Competitors $8.61 +0.18 (+2.14%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.72 +0.11 (+1.22%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. BLFS, KMTS, PLSE, TNDM, MDXG, INMD, IRMD, BBNX, EMBC, and AXGNShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include BioLife Solutions (BLFS), Kestra Medical Technologies (KMTS), Pulse Biosciences (PLSE), Tandem Diabetes Care (TNDM), MiMedx Group (MDXG), InMode (INMD), iRadimed (IRMD), Beta Bionics (BBNX), Embecta (EMBC), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors BioLife Solutions Kestra Medical Technologies Pulse Biosciences Tandem Diabetes Care MiMedx Group InMode iRadimed Beta Bionics Embecta AxoGen RxSight (NASDAQ:RXST) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals and insiders hold more shares of RXST or BLFS? 78.8% of RxSight shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer RXST or BLFS? RxSight presently has a consensus price target of $10.00, indicating a potential upside of 16.14%. BioLife Solutions has a consensus price target of $31.29, indicating a potential upside of 8.67%. Given RxSight's higher possible upside, research analysts clearly believe RxSight is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.85BioLife Solutions 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is RXST or BLFS more profitable? BioLife Solutions has a net margin of -5.39% compared to RxSight's net margin of -21.93%. BioLife Solutions' return on equity of 0.16% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-21.93% -11.56% -10.31% BioLife Solutions -5.39%0.16%0.14% Which has higher valuation and earnings, RXST or BLFS? BioLife Solutions has lower revenue, but higher earnings than RxSight. BioLife Solutions is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M2.52-$27.45M-$0.80-10.76BioLife Solutions$82.25M16.77-$20.18M-$0.12-239.92 Does the media favor RXST or BLFS? In the previous week, BioLife Solutions had 11 more articles in the media than RxSight. MarketBeat recorded 14 mentions for BioLife Solutions and 3 mentions for RxSight. RxSight's average media sentiment score of 0.98 beat BioLife Solutions' score of 0.95 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RXST or BLFS? RxSight has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. SummaryBioLife Solutions beats RxSight on 11 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$344.92M$7.83B$6.23B$10.66BDividend YieldN/A1.12%5.71%4.82%P/E Ratio-10.7627.3330.2030.21Price / Sales2.529.76590.34132.63Price / CashN/A22.8437.0161.44Price / Book1.235.2612.046.60Net Income-$27.45M$178.09M$3.32B$276.82M7 Day Performance4.49%1.32%1.89%2.58%1 Month Performance-4.97%3.23%7.68%3.76%1 Year Performance-82.91%4.47%56.01%33.84% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight2.1935 of 5 stars$8.61+2.1%$10.00+16.1%-82.6%$344.92M$139.93M-10.76220BLFSBioLife Solutions2.1047 of 5 stars$27.86+2.0%$31.29+12.3%+33.2%$1.31B$82.25M-232.15440News CoverageAnalyst ForecastInsider TradeKMTSKestra Medical Technologies0.7433 of 5 stars$26.85+9.1%$27.33+1.8%N/A$1.27B$66.40M0.00300News CoveragePLSEPulse Biosciences3.7724 of 5 stars$18.21+3.7%$22.00+20.8%+0.9%$1.18B$700K-17.34140Positive NewsUpcoming EarningsTNDMTandem Diabetes Care4.222 of 5 stars$15.54+5.1%$22.19+42.8%-52.9%$999.35M$1.00B-5.032,650Analyst ForecastMDXGMiMedx Group3.2208 of 5 stars$6.75+0.9%$12.00+77.8%+18.4%$989.85M$348.88M32.14870News CoveragePositive NewsUpcoming EarningsAnalyst DowngradeINMDInMode3.2983 of 5 stars$16.01+4.6%$16.85+5.2%-13.5%$967.73M$394.82M6.48480Positive NewsIRMDiRadimed4.5756 of 5 stars$74.69+1.7%$72.00-3.6%+55.4%$933.67M$73.24M46.10110News CoverageUpcoming EarningsInsider TradeBBNXBeta Bionics2.6783 of 5 stars$20.24+1.1%$24.44+20.8%N/A$870.27M$65.12M0.00294Analyst ForecastShort Interest ↑Gap UpEMBCEmbecta4.7291 of 5 stars$14.10+4.0%$19.00+34.8%+2.0%$793.06M$1.10B9.862,100Positive NewsAnalyst ForecastAXGNAxoGen3.5516 of 5 stars$16.97+2.3%$25.75+51.7%+36.5%$763.35M$187.34M-169.68450Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies BioLife Solutions Alternatives Kestra Medical Technologies Alternatives Pulse Biosciences Alternatives Tandem Diabetes Care Alternatives MiMedx Group Alternatives InMode Alternatives iRadimed Alternatives Beta Bionics Alternatives Embecta Alternatives AxoGen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXST Stock Alerts